🇺🇸 FDA
Pipeline program

Teplizumab

EFC18241

Phase 3 small_molecule active

Quick answer

Teplizumab for Type 1 Diabetes Mellitus is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pasteur
Indication
Type 1 Diabetes Mellitus
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials